[1]
|
王群. 新形势下我国社会保障面临的新问题及应对——基于第七次全国人口普查数据的分析[J]. 重庆行政(公共论坛), 2021(6): 105-106.
|
[2]
|
Qaseem, A., Forciea, M.A., McLean, R.M., et al. (2017) Treatment of Low Bone Densi-ty or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update from the American College of Physicians. Annals of Internal Medicine, 166, 818-839. https://doi.org/10.7326/M15-1361
|
[3]
|
Ferrari, S., Eastell, R., Napoli, N., et al. (2020) Denosumab in Postmenopausal Women with Osteoporosis and Diabetes: Sub-group Analysis of FREEDOM and FREEDOM Extension. Bone, 134, Article ID: 115268.
https://doi.org/10.1016/j.bone.2020.115268
|
[4]
|
Clemens, K.K., Jeyakumar, N., Ouedraogo, A.M., et al. (2020) Bisphosphonate and Denosumab Initiation in Older Adults in Ontario, Canada: A Population-Based Cohort Study. Ar-chives of Osteoporosis, 15, 133.
https://doi.org/10.1007/s11657-020-00796-3
|
[5]
|
Pang, K.L., Low, N.Y. and Chin, K.Y. (2020) A Review on the Role of Denosumab in Fracture Prevention. Drug Design, Development and Therapy, 14, 4029-4051. https://doi.org/10.2147/DDDT.S270829
|
[6]
|
Drake, M.T., Clarke, B.L., Oursler, M.J., et al. (2017) Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned. Endocrine Reviews, 38, 325-350. https://doi.org/10.1210/er.2015-1114
|
[7]
|
Yoo, J.I., Ha, Y.C., Won, Y.Y., et al. (2017) Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with Osteoporosis. Journal of Bone Metabo-lism, 24, 91-96.
https://doi.org/10.11005/jbm.2017.24.2.91
|
[8]
|
Jin, S.S., He, D.Q., Luo, D., et al. (2019) A Biomimetic Hierar-chical Nanointerface Orchestrates Macrophage Polarization and Mesenchymal Stem Cell Recruitment to Promote Endog-enous Bone Regeneration. ACS Nano, 13, 6581-6595.
https://doi.org/10.1021/acsnano.9b00489
|
[9]
|
Bruno, F., Carboni, N., Palumbo, P., et al. (2021) O2-O3 Che-modiscolysis: How Much, How Long? Retrospective Outcome Evaluation of Different Treatment Sessions in Partial-ly-Responder Patients. Interventional Neuroradiology, 23, 444-450. https://doi.org/10.1177/1591019917703784
|
[10]
|
Guo, L., Han, J., Guo, H., et al. (2019) Pathway and Network Analysis of Genes Related to Osteoporosis. Molecular Medicine Reports, 20, 985-994. https://doi.org/10.3892/mmr.2019.10353
|
[11]
|
Levaot, N., Simoncic, P.D., Dimitriou, I.D., et al. (2011) 3BP2-Deficient Mice Are Osteoporotic with Impaired Osteoblast and Osteoclast Functions. Journal of Clinical Investi-gation, 121, 3244-3257. https://doi.org/10.1172/JCI45843
|
[12]
|
Nishioku, T., Kubo, T., Kamada, T., et al. (2020) (-)-Epigallocatechin-3-Gallate Inhibits RANKL-Induced Osteoclastogenesis via Downregulation of NFATc1 and Sup-pression of HO-1-HMGB1-RAGE Pathway. Biomedical Research, 41, 269-277. https://doi.org/10.2220/biomedres.41.269
|
[13]
|
Xie, Y., Gao, Y., Zhang, L., et al. (2018) Involvement of Se-rum-Derived Exosomes of Elderly Patients with Bone Loss in Failure of Bone Remodeling via Alteration of Exosomal Bone-Related Proteins. Aging Cell, 17, e12758.
https://doi.org/10.1111/acel.12758
|
[14]
|
Faltermeier, C.M., Drake, J.M., Clark, P.M., et al. (2016) Functional Screen Identifies Kinases Driving Prostate Cancer Visceral and Bone Metastasis. Proceedings of the National Academy of Sciences of the United States of America, 113, E172-E181. https://doi.org/10.1073/pnas.1521674112
|
[15]
|
Huang, Y., Li, Y., Zhong, X., et al. (2017) SRC-Family Kinases Activation in Spinal Microglia Contributes to Central Sensitiza-tion and Chronic Pain after Lumbar Disc Herniation. Molecular Pain, 13.
https://doi.org/10.1177/1744806917733637
|
[16]
|
Bagnato, G., Leopizzi, M., Urciuoli, E., et al. (2020) Nuclear Functions of the Tyrosine Kinase Src. International Journal of Molecular Sciences, 21, 2675. https://doi.org/10.3390/ijms21082675
|
[17]
|
Szilveszter, K.P., Nemeth, T. and Mocsai, A. (2019) Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases. Frontiers in Immunology, 10, Article No. 1862. https://doi.org/10.3389/fimmu.2019.01862
|
[18]
|
Antonarakis, E.S., Heath, E.I., Posadas, E.M., et al. (2013) A Phase 2 Study of KX2-391, an Oral Inhibitor of Src Kinase and Tubulin Polymerization, in Men with Bone-Metastatic Castration-Resistant Prostate Cancer. Cancer Chemotherapy and Pharmacology, 71, 883-892. https://doi.org/10.1007/s00280-013-2079-z
|
[19]
|
Liu, L., Zhu, Q., Wang, J., et al. (2015) Gene Expression Changes in Human Mesenchymal Stem Cells from Patients with Osteoporosis. Molecular Medicine Reports, 12, 981-987. https://doi.org/10.3892/mmr.2015.3514
|
[20]
|
Sapkota, M., Li, L., Kim, S.W., et al. (2018) Thymol Inhibits RANKL-Induced Osteoclastogenesis in RAW264.7 and BMM Cells and LPS-Induced Bone Loss in Mice. Food and Chemical Toxicology, 120, 418-429.
https://doi.org/10.1016/j.fct.2018.07.032
|
[21]
|
王琴, 刘力, 乐意, 等. Src激酶抑制剂研究进展[J]. 中国药物化学杂志, 2021, 31(4): 312-319.
|
[22]
|
Botter, S.M., Neri, D. and Fuchs, B. (2014) Recent Advances in Osteosarcoma. Current Opinion in Pharmacology, 16, 15-23. https://doi.org/10.1016/j.coph.2014.02.002
|
[23]
|
Heusschen, R., Muller, J., Binsfeld, M., et al. (2016) SRC Kinase Inhibition with Saracatinib Limits the Development of Osteolytic Bone Disease in Multiple Myeloma. Oncotarget, 7, 30712-30729.
https://doi.org/10.18632/oncotarget.8750
|
[24]
|
Cao, H., Lei, S., Deng, H.W., et al. (2012) Identification of Genes for Complex Diseases Using Integrated Analysis of Multiple Types of Genomic Data. PLoS ONE, 7, e42755. https://doi.org/10.1371/journal.pone.0042755
|
[25]
|
Chen, H., Fang, C., Zhi, X., et al. (2020) Neobavaisoflavone Inhibits Osteoclastogenesis through Blocking RANKL Signalling-Mediated TRAF6 and c-Src Recruitment and NF-κB, MAPK and Akt Pathways. Journal of Cellular and Molecular Medicine, 24, 9067-9084. https://doi.org/10.1111/jcmm.15543
|
[26]
|
Nuche-Berenguer, B., Ramos-Álvarez, I. and Jensen, R.T. (2016) SRC Kinases Play a Novel Dual Role in Acute Pancreatitis Affecting Severity But No Role in Stimulated Enzyme Secretion. The American Journal of Physiology- Gastrointestinal and Liver Physiology, 310, G1015-G1027. https://doi.org/10.1152/ajpgi.00349.2015
|
[27]
|
Lee, J., Son, H.S., Lee, H.I., et al. (2019) Skullcapflavone II Inhibits Osteoclastogenesis by Regulating Reactive Oxygen Species and Attenuates the Survival and Resorption Function of Os-teoclasts by Modulating Integrin Signaling. FASEB Journal, 33, 2026-2036. https://doi.org/10.1096/fj.201800866RR
|
[28]
|
Takeshita, S., Fumoto, T., Ito, M., et al. (2018) Serum CTX Levels and Histomorphometric Analysis in SRC versus RANKL Knockout Mice. Journal of Bone and Mineral Metabolism, 36, 264-273.
https://doi.org/10.1007/s00774-017-0838-3
|
[29]
|
Brar, K.S. (2010) Prevalent and Emerging Therapies for Osteo-porosis. Medical Journal Armed Forces India, 66, 249- 254. https://doi.org/10.1016/S0377-1237(10)80050-4
|
[30]
|
Huang, Y., Ren, K., Yao, T., et al. (2020) MicroRNA-25-3p Regulates Osteoclasts through Nuclear Factor IX. Biochemical and Biophysical Research Communications, 522, 74-80. https://doi.org/10.1016/j.bbrc.2019.11.043
|
[31]
|
Stone, J.A., McCrea, J.B., Witter, R., et al. (2019) Clinical and Translational Pharmacology of the Cathepsin K Inhibitor Odanacatib Studied for Osteoporosis. British Journal of Clinical Pharmacology, 85, 1072-1083.
https://doi.org/10.1111/bcp.13869
|
[32]
|
Hannon, R.A., Clack, G., Rimmer, M., et al. (2010) Effects of the SRC Ki-nase Inhibitor Saracatinib (AZD0530) on Bone Turnover in Healthy Men: A Randomized, Double-Blind, Place-bo-Controlled, Multiple-Ascending-Dose Phase I Trial. Journal of Bone and Mineral Research, 25, 463-471. https://doi.org/10.1359/jbmr.090830
|
[33]
|
Lotinun, S., Ishihara, Y., Nagano, K., et al. (2019) Cathepsin K-Deficient Osteocytes Prevent Lactation-Induced Bone Loss and Parathyroid Hormone Suppression. Journal of Clinical Investiga-tion, 129, 3058-3071.
https://doi.org/10.1172/JCI122936
|
[34]
|
Gavali, S., Gupta, M.K., Daswani, B., et al. (2019) LYN, a Key Mediator in Estrogen-Dependent Suppression of Osteoclast Differentiation, Survival, and Function. Biochimica et Biophysica Ac-ta—Molecular Basis of Disease, 1865, 547-557. https://doi.org/10.1016/j.bbadis.2018.12.016
|
[35]
|
Portal-Núñez, S., Ardura, J.A., Lozano, D., et al. (2018) Parathyroid Hormone-Related Protein Exhibits Antioxidant Features in Osteo-blastic Cells through Its N-terminal and Osteostatin Domains. Bone & Joint Research, 7, 58-68.
https://doi.org/10.1302/2046-3758.71.BJR-2016-0242.R2
|
[36]
|
Qiao, Q., Song, Y.L. and Li, F.L. (2018) Sema-phorin 3A-Stimulated Bone Marrow Mesenchymal Stem Cells Sheets Promotes Osteogenesis of Type 2 Diabetic Rat. Chinese Journal of Stomatology, 53, 333-338.
|
[37]
|
Christiansen, A.R., Lipshultz, L.I., Hotaling, J.M., et al. (2020) Se-lective Androgen Receptor Modulators: The Future of Androgen Therapy? Translational Andrology and Urology, 9, S135-S148. https://doi.org/10.21037/tau.2019.11.02
|
[38]
|
Kobayakawa, M., Matsubara, T., Mizokami, A., et al. (2020) Kif1c Regulates Osteoclastic Bone Resorption as a Downstream Molecule of p130Cas. Cell Biochemistry and Function, 38, 300-308. https://doi.org/10.1002/cbf.3476
|
[39]
|
Brömme, D., Panwar, P. and Turan, S. (2016) Ca-thepsin K Osteoporosis Trials, Pycnodysostosis and Mouse Deficiency Models: Commonalities and Differences. Expert Opinion on Drug Discovery, 11, 457-472.
https://doi.org/10.1517/17460441.2016.1160884
|
[40]
|
Zheleznyak, A., Mixdorf, M., Marsala, L., et al. (2021) Or-thogonal Targeting of Osteoclasts and Myeloma Cells for Radionuclide Stimulated Dynamic Therapy Induces Multidi-mensional Cell Death Pathways. Theranostics, 11, 7735- 7754. https://doi.org/10.7150/thno.60757
|
[41]
|
Rucci, N., Susa, M. and Teti, A. (2008) Inhibition of Protein Kinase c-SRC as a Therapeutic Approach for Cancer and Bone Metas-tases. Anti-Cancer Agents in Medicinal Chemistry, 8, 342-349.
https://doi.org/10.2174/187152008783961905
|